JimLur, Even when it's manufacturer Merck says there is no evidence covid has any role in treating covid it's weird politicians still push bills in support of it as a covid treatment.
Ivermectin: How false science created a Covid 'miracle' drug [...] In February, Merck - one of the companies that makes the drug - said there was "no scientific basis for a potential therapeutic effect against Covid-19". ---- [INSERT: Zardiw, dropdeadfred, Ivermectin: why a potential COVID treatment isn’t recommended for use [...] This alone should shut you up on ivermectin February 4, 2021 11:45 am ET KENILWORTH, N.J., Feb. 4, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic. Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to-date, our analysis has identified: * No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies; * No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and; * A concerning lack of safety data in the majority of studies. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165759492] ---- In South Africa, the drug has become a battleground... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167396544
Noted also Dr. Paul Marik still around, "Dr. Paul Marik, neurocritical care doctor who has published more than 600 peer review papers in his field, testified that Ivermectin, “is one of the safest drugs on the face on this planet.”"
Being a safe drug doesn't exactly make it suitable for treating covid. Marik still courts controversy:
Controversial Doc Resigns From Medical School — Paul Marik, MD, has been embroiled in legal battle with Virginia hospital
by Kristina Fiore, Director of Enterprise & Investigative Reporting, MedPage Today January 5, 2022
Paul Marik, MD, who has been in a legal battle with his hospital over prescribing ivermectin and other COVID-19 treatments, announced that he resigned from his position at Eastern Virginia Medical School (EVMS).
INSERT: dropdeadfred, Ivermectin: why a potential COVID treatment isn’t recommended for use Ivermectin: we know it’s good for cows, but is it good for COVID? Farlap/Alamy Stock Photo
"This was not an easy decision to make, but I felt it was time to focus my attention and energy to other interests in both academia and public health," Marik said in the statement.
In an emailed statement, Vincent Rhodes, PhD, associate vice president and chief communications & marketing officer for EVMS, confirmed that Marik "resigned his position at EVMS effective December 31 to pursue other interests."
It's not clear whether Marik still has a position at Sentara Norfolk General Hospital. A spokesperson for Sentara Health did not return a request for comment as of press time.
Marik and the hospital have been embroiled in a legal battle over prescribing certain treatments for COVID-19, including ivermectin.
Marik filed a lawsuit against the hospital .. https://www.medpagetoday.com/special-reports/exclusives/95725 .. on November 9 over its ban on certain therapies. That same day, a paper Marik had published on his MATH+ Hospital Treatment Protocol for COVID-19 was retracted after Sentara raised concerns about it with the Journal of Intensive Care Medicine.
The retraction notice .. https://journals.sagepub.com/doi/pdf/10.1177/0885066620973585 .. cited a communication it received from Sentara Norfolk General Hospital that questioned "the accuracy of COVID-19 hospital mortality data reported in the article pertaining to Sentara."
According to an excerpt of Sentara's communication published in the retraction notice, the hospital "conducted a careful review of our data for patients with COVID-19 from March 22, 2020 to July 20, 2020, which shows that among the 191 patients referenced in Table 2 that the mortality rate was 10.5%, rather than 6.1%. In addition, of those 191 patients, only 73 patients (38.2%) received at least 1 of the 4 MATH+ therapies, and their mortality rate was 24.7%. Only 25 of 191 patients (13.1%) received all 4 MATH+ therapies, and their mortality rate was 28%."
On November 23, a judge in Virginia granted part of Sentara's motion to dismiss Marik's case, but it allowed one of Marik's claims to proceed. The status of the lawsuit is not clear, and Marik's lawyer did not return a request for comment as of press time.
This isn't the first time one of Marik's treatment protocols has been the source of controversy in the critical care medicine community. He developed the HAT protocol for sepsis -- a combination of hydrocortisone, ascorbic acid (vitamin C), and thiamine. A 2017 observational study on the protocol, published in CHEST .. https://pubmed.ncbi.nlm.nih.gov/27940189/ .. , garnered excitement, but the findings weren't borne out in subsequent clinical trials.
Marik was a professor of medicine and the chief of pulmonary and critical care medicine at EVMS, where he started in 2009, and earned tenure in 2014, according to his statement. He started practicing medicine at Baragwanath Hospital in South Africa, then moved to the U.S. in 1992, taking positions at Detroit Receiving Hospital and Wayne State University.
He subsequently held several appointments at other medical schools in the Northeast and Mid-Atlantic regions before arriving at EVMS, his statement noted.
author['full_name']
Kristina Fiore leads MedPage’s enterprise & investigative reporting team. She’s been a medical journalist for more than a decade and her work has been recognized by Barlett & Steele, AHCJ, SABEW, and others. Send story tips to k.fiore@medpagetoday.com. Follow
Market Data 
Markets 
AI
